Although not PD-specific, the paper highlights astrocyte-expressed extracellular matrix and adhesion targets that could be pharmacologically modulated or repurposed as starting points for astrocyte-centered neuroprotective strategies relevant to Parkinson's disease.

Findings clarify cortical hemodynamic and connectivity mechanisms by which external cueing alleviates freezing of gait, supporting non-pharmacological therapies and potential cortical targets/biomarkers for neuromodulation, but provide limited direct molecular targets for drug discovery.

Although not addressing molecular targets, the result is clinically relevant for tailoring and stratifying rehabilitation interventions (and related trials) by sedentary behavior to better address perceived-versus-actual balance and potentially reduce fall risk.

Offers patient-centered evidence to inform pragmatic clinical trial design, outcome selection, and deployment strategies for robotic/home-based rehabilitation in Parkinson's care, but contains no mechanistic or direct therapeutic discovery insights.

While it offers limited direct insight into PD neuroprotective mechanisms, the paper provides in vivo safety/toxicity data, a zebrafish platform for repurposing screens, and bioinformatic links that could inform comorbidity studies or hypotheses for future repurposing efforts.

Although not mechanistic, these real-world patient-reported findings are useful for informing clinical prescribing, shared decision-making, prioritizing outcomes for trials of motor-fluctuation therapies, and improving implementation of adjunctive COMT inhibitor treatment.

Although it provides little mechanistic or therapeutic discovery content, these practical guidelines can enhance implementation, patient access, and the design of remote cognitive intervention trials in PD, aiding clinical delivery and translational research readiness.

Findings support a feasible, safe non-pharmacological intervention that may reduce fall risk and boost cognition—valuable for symptomatic management and justifying controlled trials, but of limited direct relevance to molecular therapeutic discovery.

While not addressing molecular or disease-modifying targets, the findings are clinically relevant for improving mental health care delivery, quality of life, and potentially treatment adherence in Parkinson's patients, which can indirectly affect clinical outcomes.

VR is valuable for symptomatic rehabilitation, objective outcome measurement, and potential digital biomarkers in PD trials, but it offers minimal actionable molecular or target-based insights for Parkinson's therapeutic discovery.

This trial is clinically useful for reducing alcohol-related brain health risks in older adults but has limited direct value for Parkinson's therapeutic discovery because it excludes PD patients and provides no mechanistic, biomarker, or targetable insights relevant to PD pathogenesis or drug…

Though focused on pediatric GNAO1 encephalopathy, the study provides circuit-specific dissection of G protein signaling, molecular biomarkers, and a repurposed intervention (caffeine), offering experimental strategies and translational leads that could inform Parkinson's motor-circuit targeting and…

Identifies DNAJC6 as a disease-modifying target that connects key PD pathways (α-synuclein, lysosomes, mitochondria, inflammation, LRRK2) and validates a translational intervention (AAV-CRISPRa) with cell-type specificity, making it highly relevant for therapeutic development and biomarker efforts.

Provides actionable, validated targets—EMC4 for enhancing ER-autophagy to broadly lower α-syn aggregation and OXR1/mitochondrial pathways as modulators of polymorph-specific aggregation—making these high-priority leads for Parkinson’s therapeutic discovery and target development.

Provides a blood-correlated biomarker and a mechanistic, druggable LINC-EPS→PGC-1α anti-ferroptosis axis that supports translational strategies (gene therapy/lncRNA modulation or PGC-1α activation/repurposing) for disease-modifying PD interventions.

By linking mitochondrial ROS and OPA1-dependent dynamics to caspase-3/GSDME-driven neuronal apoptosis with in vivo dopaminergic loss, the work identifies actionable targets (mito-ROS, OPA1, caspase-3/GSDME) and an environmental etiologic axis that can inform antioxidant, mitochondrial-dynamics, or…

These minimally invasive, mechanism-linked mtDNA biomarkers can help stratify patients by mitochondrial involvement and enrich/monitor cohorts for mitochondrial-targeted interventions, increasing translational and trial-readiness value despite limited standalone diagnostic accuracy.

This provides a mechanistically grounded, actionable proof-of-concept that targeted lysosomal re-acidification can reduce pathogenic α‑synuclein and neurodegeneration, highlighting a novel therapeutic strategy warranting advancement to mammalian models and translational development.

Provides clinically accessible biomarkers and genetic evidence implicating ferroptosis in PD progression, offering a translational path to stratify patients for trials of ferroptosis-modulating therapies and for targeted repurposing (e.g., iron chelators or ferroptosis inhibitors).

Provides a non-invasive, pragmatic approach to infer alpha-synuclein pathology that can help enrich and triage participants for biomarker-driven trials and reduce reliance on CSF sampling, aiding therapeutic development and patient stratification.